Early results from a phase Ia/b dose escalation trial evaluating the safety and tolerability of CG-806 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL) or non-Hodgkin’s lymphomas (NHL) were presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020, held from April 27-28, 2020.1
“CG-806 is an orally bioavailable non-covalent kinase inhibitor that potently inhibits key clusters of related kinases involved in oncogenic signaling,” Rafael Bejar, MD, PhD, chief medical officer for Aptose, said during a poster presentation of the data at AACR.2 “These include the tight cluster of kinases that include BTK, ITK, and related kinases.”
The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for…